MCID: SPR001
MIFTS: 30

Superficial Urinary Bladder Cancer

Categories: Cancer diseases, Nephrological diseases

Aliases & Classifications for Superficial Urinary Bladder Cancer

MalaCards integrated aliases for Superficial Urinary Bladder Cancer:

Name: Superficial Urinary Bladder Cancer 12 15
Carcinoma of Urinary Bladder, Superficial 73
Superficial Urinary Bladder Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:7371
NCIt 50 C27474
SNOMED-CT 68 425231005
UMLS 73 C1336527

Summaries for Superficial Urinary Bladder Cancer

Disease Ontology : 12 A carcinoma of bladder that originates in the epithelial cells (the internal lining) of the bladder wall and is limited to this area.

MalaCards based summary : Superficial Urinary Bladder Cancer, also known as carcinoma of urinary bladder, superficial, is related to bladder cancer and male reproductive organ cancer. An important gene associated with Superficial Urinary Bladder Cancer is TAAR1 (Trace Amine Associated Receptor 1), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Colorectal Cancer Metastasis. The drugs Gemcitabine and Celecoxib have been mentioned in the context of this disorder. Affiliated tissues include lung and liver.

Related Diseases for Superficial Urinary Bladder Cancer

Diseases related to Superficial Urinary Bladder Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 bladder cancer 10.3
2 male reproductive organ cancer 9.6 CCND1 IGFBP3
3 lynch syndrome 9.5 CCND1 MSH3 TGFBR2
4 pseudoxanthoma elasticum 8.6 NOMO1 NOMO2 NOMO3

Symptoms & Phenotypes for Superficial Urinary Bladder Cancer

Drugs & Therapeutics for Superficial Urinary Bladder Cancer

Drugs for Superficial Urinary Bladder Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 77)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
2
Celecoxib Approved, Investigational Phase 2, Phase 3 169590-42-5 2662
3
Docetaxel Approved, Investigational Phase 3,Phase 2 114977-28-5 148124
4
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
5
Ethanol Approved Phase 3 64-17-5 702
6
Mineral oil Approved, Vet_approved Phase 3 8042-47-5
7
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
8
BCG vaccine Investigational Phase 3,Phase 2,Phase 1
9
Fenretinide Investigational Phase 3 65646-68-6
10 Alkylating Agents Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1
11 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
12 Mitomycins Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1
13 Nucleic Acid Synthesis Inhibitors Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1
14 Vaccines Phase 3,Phase 2,Phase 1
15 Anti-Bacterial Agents Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1
16 Antibiotics, Antitubercular Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1
17 Pharmaceutical Solutions Phase 3,Phase 1,Phase 2
18 Analgesics Phase 2, Phase 3
19 interferons Phase 2, Phase 3,Phase 1
20 Cyclooxygenase 2 Inhibitors Phase 2, Phase 3
21 Cyclooxygenase Inhibitors Phase 2, Phase 3
22 Analgesics, Non-Narcotic Phase 2, Phase 3
23 Viscum album peptide Phase 3,Phase 1,Phase 2
24 Peripheral Nervous System Agents Phase 2, Phase 3
25 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
26 Anti-Infective Agents Phase 2, Phase 3,Phase 3,Phase 1
27 Interferon-alpha Phase 2, Phase 3,Phase 1
28 Anti-HIV Agents Phase 3,Phase 1,Phase 2
29 Antiparasitic Agents Phase 3,Phase 1
30 Antiprotozoal Agents Phase 3,Phase 1
31 Anti-Inflammatory Agents Phase 2, Phase 3
32 Anti-Retroviral Agents Phase 3,Phase 1,Phase 2
33 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
34 Antirheumatic Agents Phase 2, Phase 3
35 Antimetabolites Phase 3,Phase 2,Phase 1
36 Antiviral Agents Phase 2, Phase 3,Phase 3,Phase 1
37 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
38 Antimitotic Agents Phase 3,Phase 1,Phase 2
39 Eicosapentaenoic acid ethyl ester Phase 3
40 Platelet Aggregation Inhibitors Phase 3
41 Liver Extracts Phase 3
42 European Mistletoe Nutraceutical Phase 3,Phase 1,Phase 2
43 Cola Nutraceutical Phase 3
44 Omega 3 Fatty Acid Nutraceutical Phase 3
45
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
46
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
47
Valrubicin Approved Phase 2 56124-62-0 41744
48
Trioxsalen Approved Phase 1, Phase 2 3902-71-4 5585
49
Metformin Approved Phase 2 657-24-9 14219 4091
50
Apaziquone Investigational Phase 2 114560-48-4 5813717

Interventional clinical trials:

(show top 50) (show all 56)
# Name Status NCT ID Phase Drugs
1 Efficacy of Distilled Water Versus Mitomycin C on Preventing Recurrences of Bladder Cancer After Transurethral Resection Unknown status NCT00816075 Phase 2, Phase 3 distilled water
2 Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer Completed NCT01442519 Phase 3 electromotive mitomycin
3 Combined Use of BCG and Interferon Alpha in Bladder Cancer Completed NCT00330707 Phase 2, Phase 3 Bacillus Calmette Guerin and interferon alpha
4 Preoperative Intravesical Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer Completed NCT01149174 Phase 3 Mitomycin-C 40 mg
5 Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer Completed NCT00004154 Phase 3 Fenretinide
6 Eflornithine in Treating Patients With Bladder Cancer Completed NCT00003814 Phase 3 eflornithine
7 Celecoxib in Treating Patients With Bladder Cancer Completed NCT00006124 Phase 2, Phase 3 celecoxib;placebo
8 S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Completed NCT00445601 Phase 3 gemcitabine hydrochloride
9 Therapeutic Instillation of Mistletoe Recruiting NCT02106572 Phase 3 abnobaVISCUM 900;Mitomycin C
10 Study of the Efficacy of Maintenance Therapy Using Uracil-tegafur (UFT) or Bacille Calmette-Guerin (BCG) for the Prevention of Recurrences of Superficial Bladder Cancer (EMBARK Study) Recruiting NCT01082510 Phase 3 Bacille Calmette-Guerin;uracil-tegafur
11 Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC Recruiting NCT02982395 Phase 3 Nanoxel®M;Mitomycin-C
12 EPA for Metastasis Trial 2 Recruiting NCT03428477 Phase 3 Icosapent Ethyl
13 A Study to Evaluate INSTILADRIN® in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive NMIBC Active, not recruiting NCT02773849 Phase 3
14 Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer Terminated NCT00384891 Phase 3 Bacillus Calmette-Guérin
15 Instillation of Gemcitabine in Patients With Superficial Bladder Cancer Terminated NCT00191477 Phase 3 Gemcitabine;Placebo
16 First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC Withdrawn NCT01284205 Phase 3
17 SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I Withdrawn NCT02254915 Phase 3 Bacillus Calmette-Guérin
18 Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer Unknown status NCT00595088 Phase 2
19 A Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Patients With Superficial Bladder Cancer Unknown status NCT00318643 Phase 1, Phase 2 Chemophase;Mitomycin C
20 Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer Completed NCT02007005 Phase 1, Phase 2 abnobaVISCUM Fraxini
21 Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk. Completed NCT00191711 Phase 2 Gemcitabine
22 A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer Completed NCT00192049 Phase 2 Gemcitabine;mitomycin C
23 Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer Completed NCT00322699 Phase 1, Phase 2 Photofrin
24 Bacillus of Calmette and Guerin (BCG) Versus Gemcitabine For Intravesical Therapy In High Risk Superficial Bladder Cancer Completed NCT00696579 Phase 1, Phase 2 BCG;gemcitabine
25 Phase II Trial of EOquin in High-risk Superficial Bladder Cancer Completed NCT00141531 Phase 2 Apaziquone
26 AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer Completed NCT00003759 Phase 2 valrubicin
27 Safety and Proof of Concept Study of Intravesical DTA-H19 in Patients With Superficial Bladder Cancer Completed NCT00393809 Phase 1, Phase 2 DTA-H19
28 Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer Completed NCT01687244 Phase 2 INSTILADRIN
29 Intravesical Chemotherapy Treatment of Superficial Bladder Cancer Completed NCT00491114 Phase 2 Gemcitabine
30 Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer Completed NCT00088946 Phase 2 erlotinib hydrochloride
31 The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer Completed NCT01697306 Phase 2 Gemcitabine 2 g;BCG Vaccine
32 BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer Completed NCT00004122 Phase 2
33 S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin Completed NCT00234039 Phase 2 gemcitabine hydrochloride
34 Paclitaxel in Treating Patients With Early-Stage Bladder Cancer Completed NCT00002917 Phase 1, Phase 2 paclitaxel
35 Intravesical Natural Baobab Oil in the Management of BCG-induced Lower Urinary Tract Symptoms Completed NCT01939756 Phase 1, Phase 2
36 A Randomized Study Evaluating the Feasibility and Activity of Three Different Combination With Gemcitabine as First Line Therapy for Non Small Cell Lung Cancer Completed NCT00191490 Phase 2 Gemcitabine;docetaxel;cisplatin
37 Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer Recruiting NCT02281383 Phase 2
38 Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment Recruiting NCT01489813 Phase 2 Genistein;Sugar pill
39 Investigating Bladder Chemotherapy Instead of Surgery for Low Risk Bladder Cancer Active, not recruiting NCT02070120 Phase 2 Mitomycin C
40 Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer Not yet recruiting NCT03379909 Phase 2 Metformin
41 A Study for Treatment of Superficial Bladder Cancer Using OGX-427 Unknown status NCT00959868 Phase 1 OGX-427
42 Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure Unknown status NCT00109655 Phase 1
43 Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer Completed NCT00782587 Phase 1 Chemophase
44 1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer Completed NCT01162785 Phase 1 SCH 721015
45 Suramin in Treating Patients With Recurrent Bladder Cancer Completed NCT00006476 Phase 1 suramin
46 MK-3475/BCG in High Risk Superficial Bladder Cancer Recruiting NCT02324582 Phase 1 Intravenous MK-3475/ Intravesical BCG
47 Immunological Response to Intravesical BCG Therapy of Superficial Bladder Cancer by Prior Administration of RUTI® Suspended NCT03191578 Phase 1 RUTI®;Placebo
48 Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer Withdrawn NCT00014287 Phase 1 gemcitabine hydrochloride
49 Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer Withdrawn NCT00880854 Phase 1 BCG and CP-675,206
50 Cost-Effectiveness in Bladder Cancer Unknown status NCT00126958

Search NIH Clinical Center for Superficial Urinary Bladder Cancer

Genetic Tests for Superficial Urinary Bladder Cancer

Anatomical Context for Superficial Urinary Bladder Cancer

MalaCards organs/tissues related to Superficial Urinary Bladder Cancer:

41
Lung, Liver

Publications for Superficial Urinary Bladder Cancer

Articles related to Superficial Urinary Bladder Cancer:

# Title Authors Year
1
A case of disseminated Mycobacterium bovis 2 years post-intravesicular Bacillus Calmette-GuAcrin therapy for superficial urinary bladder cancer. ( 28677313 )
2017
2
[The p53 positivity in non-tumor mucosa in patients with superficial urinary bladder cancer]. ( 17310587 )
2007
3
Adjuvant intravesical treatment with a standardized mistletoe extract to prevent recurrence of superficial urinary bladder cancer. ( 16334168 )
2005
4
Role of ultrasonography and urinary cytology in diagnosing recurrence of superficial urinary bladder cancer compared to cystoscopy. ( 11692897 )
2001
5
Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer. ( 10398139 )
1999
6
Superficial urinary bladder cancer. Results from the Finnbladder studies and a review on instillation treatments. ( 8291866 )
1993
7
Instillation therapy in superficial urinary bladder cancer. Finnbladder Group. ( 1785001 )
1991
8
Adriamycin instillations as recurrence prophylaxis in superficial urinary bladder cancer. ( 6508201 )
1984

Variations for Superficial Urinary Bladder Cancer

Expression for Superficial Urinary Bladder Cancer

Search GEO for disease gene expression data for Superficial Urinary Bladder Cancer.

Pathways for Superficial Urinary Bladder Cancer

Pathways related to Superficial Urinary Bladder Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.6 IGFBP3 PTCRA TGFBR2
2 11.35 CCND1 MSH3 TGFBR2
3 11 CCND1 IGFBP3 TGFBR2

GO Terms for Superficial Urinary Bladder Cancer

Biological processes related to Superficial Urinary Bladder Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to estrogen GO:0043627 9.16 CCND1 TGFBR2
2 animal organ regeneration GO:0031100 8.96 CCND1 TGFBR2
3 response to steroid hormone GO:0048545 8.62 CCND1 TGFBR2

Molecular functions related to Superficial Urinary Bladder Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 carbohydrate binding GO:0030246 8.8 NOMO1 NOMO2 NOMO3

Sources for Superficial Urinary Bladder Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....